NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tixagevimab-cilgavimab for preventing COVID-19 ID6136

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)	
Company	General	
AstraZeneca (tixagevimab-	All Wales Therapeutics and Toxicology	
cilgavimab)	Centre	
	Allied Health Professionals Federation	
Patient/carer groups	Board of Community Health Councils in	
 Action for Pulmonary Fibrosis 	Wales	
 Addenbrookes Liver Transplant 	British National Formulary	
Association	Care Quality Commission	
African Caribbean Leukaemia Trust	Chest, Heart and Stroke Scotland	
Allergy UK	Department of Health, Social Services	
Anaphylaxis UK	and Public Safety for Northern Ireland	
Anthony Nolan	Diabetes UK Cymru	
AOFAC Foundation	Healthcare Improvement Scotland	
Aplastic Anaemia Trust	Medicines and Healthcare products	
BAME Health collaborative	Regulatory Agency	
Black Health Agency for Equality	National Association of Primary Care	
Blood Cancer UK	National Pharmacy Association	
Blood Pressure UK	NHS Alliance	
British Liver Trust	NHS Confederation	
British Sjögren's Syndrome	Northern Ireland Chest, Heart and	
Association	Stroke Association	
Cancer Black Care	Scottish Medicines Consortium	
Cancer Equality	Welsh Health Specialised Services	
Cancer52	Committee	
Cardiomyopathy UK		
Cardiovascular Care Partnership	Possible comparator companies	
Chronic Lymphocytic Leukaemia	None	
Support Association		
Chronic Myeloid Leukaemia Support	Relevant research groups	
Group	Asthma, Allergy and Inflammation	
CovidAid	Research Charity	
Crohn's & Colitis UK	British Neurological Research Trust	
DKMS	British Society for Cardiovascular	
Diabetes UK	Research	
Diabetes Research and Wellness	Cardiac and Cardiology Research Dept,	
Foundation	Barts	
Down's Syndrome Association	Cochrane Acute Respiratory Infections	

Provisional stakeholder list for the evaluation of tixagevimab–cilgavimab for preventing COVID-19 ID6136 Issue date: July 2022

Co	onsultees		ommentators (no right to submit or opeal)
	Encephalitis Society Evusheld for the UK Genetic Alliance UK GUTS UK Helen Rollason Cancer Charity HEART UK HIV i-Base Immunodeficiency UK Independent Age Independent Cancer Patients Voice InDependent Diabetes Trust JDRF Kidney Care UK Kidney Research UK Leukaemia Cancer Society Leukaemia Care Liver4Life Long COVID SOS Long Covid Support Lupus UK Lymphoma Action Macmillan Cancer Support Maggie's Centres Marie Curie MDS UK Patient Support Group Mencap Metabolic Support UK MPN Voice MS Society MS-UK Multiple Sclerosis National Therapy Centres Multiple Sclerosis Trust Myeloma UK NAM National AIDS Trust National Aidney Federation	ар • • • • • • • • • • • • • • • • • • •	` <u> </u>
•	National Kidney Federation National Rheumatoid Arthritis Society Network of Sikh Organisations Obesity UK PBC Foundation Positively UK Polycystic Kidney Disease Charity	<u>A</u> • •	ssociated Public Health groups Faculty of Public Health Royal Society for Public Health Public Health Wales UK Health Security Agency

Consultees	Commentators (no right to submit or appeal)
 Pumping Marvellous Foundation Race on the Agenda Race Equality Foundation Sarcoidosis UK Somerville Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Terrence Higgins Trust Thrombosis UK Healthcare professional groups Association for the Study of Obesity Association of British Clinical 	
 Diabetologists Association of Cancer Physicians Association of Clinical Biochemists - Microbiology Section British Association for Nursing in Cardiovascular Care British Association for Sexual Health and HIV British Association for the Study of the 	
 Liver (BASL) British Association of Urological Nurses British Cardiovascular Society British Committee for Standards in Haematology British Geriatrics Society British Heart Foundation British HIV Association British Infection Association 	
 British Nuclear Cardiology Society British Psychosocial Oncology Society British Renal Society British Society for Allergy and Clinical Immunology British Society for Haematology British Society for Haemostasis and Thrombosis British Society for Heart Failure British Society for Immunology British Society for Rheumatology British Society of Blood and Marrow 	

Provisional stakeholder list for the evaluation of tixagevimab–cilgavimab for preventing COVID-19 ID6136 Issue date: July 2022

Consultees	Commentators (no right to submit or appeal)
Transplantation and Cellular Therapy British Thoracic Society Cancer Research UK Clinical Leaders of Thrombosis Faculty of Pharmaceutical Medicine Infection Prevention Society National Clinical Expert group for Immunocompromised National Heart and Lung Institute NHS Blood and Transplant Primary Care Diabetes Society Primary Care Rheumatology and Musculoskeletal Medicine Society Renal Association Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Cardiological Science and Technology Society for Bendocrinology Society for General Microbiology Society for General Microbiology Society of Vascular Nurses Therapists in MS TREND UK UK Clinical Pharmacy Association UK Clinical Virology Network UK CLL Forum UK Kidney Association UK Multiple Sclerosis Specialist Nurses Association UK Oncology Nursing Society UK Primary Immunodeficiency Network UK Renal Pharmacy Group Vascular Society of Great Britain and Ireland	appeal)
Others	

Provisional stakeholder list for the evaluation of tixagevimab–cilgavimab for preventing COVID-19 ID6136 Issue date: July 2022

Consultees	Commentators (no right to submit or appeal)
 Department of Health and Social Care NHS England Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Provisional stakeholder list for the evaluation of tixagevimab—cilgavimab for preventing COVID-19 ID6136 Issue date: July 2022

¹ Non company consultees are invited to submit statements relevant to the group they are representing.